Innovative Approaches to Reducing Treatment Burden in Age-related Macular Degeneration and Diabetic Macular Edema

Author(s)/Faculty: Rishi P. Singh, MD; Dennis M. Marcus, MD
Release Date: 8/5/2021Expiration Date: 8/4/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0.75
Content Type: LectureProvider:
Less than optimal visual acuity gains in patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) receiving intravitreal anti-vascular endothelial growth factor (VEGF) therapy have been associated with loss of compliance due to treatment burden. To address the issue of treatment burden, a number of novel strategies are currently being evaluated that have the potential to lengthen the dosing interval while enhancing visual acuity gains. These strategies include novel delivery systems, gene therapy, and agents that extend dosing intervals while targeting novel pathways. In this CME activity, experts in the field will summarize new evidence on novel delivery systems that reduce the need for frequent anti-VEGF injections, and assess emerging therapies with unique mechanisms of action that can lengthen the time between treatments for patients with nAMD and DME.